In Devices, the Exit Door Stays Ajar--Barely
Over the past several years as the public market has all but turned its back on small-cap medical devices, the industry's saving grace has been the acquisition appetite of large medical device firms who were willing to pay reasonable and sometimes even spectacular prices for samll companies with promising technology. But over the past year or so, even this exit vehicle for small cap companies seems to be disappearing.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.